Negative in Ames, in vitro chromosome aberration and rat bone marrow micronucleus; positive in vitro micronucleus (likely aneugenic)
“In genotoxicity studies, deuruxolitinib was negative in the Ames test, an in vitro chromosome aberration assay, and an in vivo rat bone marrow micronucleus assay. It was positive in an in vitro micronucleus assay.”
✓ VerifiedFDA multi-discipline review, p. 45Source ↗
Carcinogenicity
6-month rasH2 mouse and 2-year rat oral studies: not carcinogenic
“Deuruxolitinib was not carcinogenic in a 6-month oral transgenic mouse carcinogenicity study or a 2-year oral rat carcinogenicity study.”
✓ VerifiedFDA multi-discipline review, p. 45Source ↗
Reproductive & developmental
Rat EFD: lower fetal weight and skeletal malformations at 60 mg/kg/day without significant maternal toxicity
“In an embryo-fetal toxicity study in rats, lower fetal weight and increased skeletal malformations were noted at 60 mg/kg/day, with no significant maternal toxicity observed.”
✓ VerifiedFDA multi-discipline review, p. 45Source ↗
Safety pharmacology
Dog CV study: 10 mg/kg caused mild transient BP decrease, heart rate increase and QT interval decrease
“a single oral dose of 10 mg/kg deuruxolitinib induced mild transient decreases in blood pressure, which correlated with mild transient increases in heart rate and decreases in QT interval.”
✓ VerifiedFDA multi-discipline review, p. 47Source ↗
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative